Last reviewed · How we verify
DTaP
DTaP is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria toxin, tetanus toxin, and pertussis antigens.
DTaP is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria toxin, tetanus toxin, and pertussis antigens. Used for Prevention of diphtheria, tetanus, and pertussis in infants and children.
At a glance
| Generic name | DTaP |
|---|---|
| Also known as | Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Infanrix® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) |
| Sponsor | China National Biotec Group Company Limited |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
DTaP contains inactivated toxoids (diphtheria and tetanus) and acellular pertussis antigens that trigger adaptive immune responses, generating protective antibodies and cellular immunity. Upon exposure to these pathogens, the primed immune system rapidly produces neutralizing antibodies and cell-mediated responses to prevent disease or reduce severity.
Approved indications
- Prevention of diphtheria, tetanus, and pertussis in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Fussiness or irritability
- Drowsiness
- Loss of appetite
Key clinical trials
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations (PHASE4)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTaP CI brief — competitive landscape report
- DTaP updates RSS · CI watch RSS
- China National Biotec Group Company Limited portfolio CI